Published online July 1, 2008
PEDIATRICS Vol. 122 No. 1 July 2008, pp. 119-124 (doi:10.1542/peds.2007-0967)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Jangaard, K. A.
Right arrow Articles by Allen, A. C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jangaard, K. A.
Right arrow Articles by Allen, A. C.
Related Collections
Right arrow Premature & Newborn

ARTICLE

Outcomes in a Population of Healthy Term and Near-Term Infants With Serum Bilirubin Levels of ≥325 µmol/L (≥19 mg/dL) Who Were Born in Nova Scotia, Canada, Between 1994 and 2000

Krista A. Jangaard, MDa, Deshayne B. Fell, MScb, Linda Dodds, PhDb and Alexander C. Allen, MDa,b

a Department of Neonatal-Perinatal Medicine
b Perinatal Epidemiology Research Unit, Dalhousie University, Halifax, Canada

OBJECTIVE. The goal was to study the incidence of kernicterus, developmental delay, autism, cerebral palsy, and hearing loss in infants with peak total serum bilirubin levels of ≥325 µmol/L (≥19 mg/dL), compared with infants with less-severe or no hyperbilirubinemia, in a population of healthy term and late preterm infants.

METHODS. Prospectively gathered, standardized, maternal and neonatal data for infants at ≥35 weeks of gestation who were born between January 1, 1994, and December 31, 2000, were extracted from the Nova Scotia Atlee Perinatal Database. Infants with Rh factor isoimmunization, significant congenital or chromosomal abnormalities, or severe peripartum asphyxia were excluded. Comparisons were made on the basis of peak total serum bilirubin levels. Diagnoses were obtained through data linkage with the Medical Services Insurance Database for office visits and the Canadian Institute for Health Information Database for hospital admissions. The registration file provided information allowing calculation of follow-up times, which were determined for each separate outcome. Follow-up periods ranged from 2 to 9 years, with the end point being the first time the diagnostic code was encountered in either database. Cox proportional-hazards regression analyses were used to examine the relationships between outcomes and total serum bilirubin levels.

RESULTS. Of 61238 infants included in the study cohort, 4010 (6.7%) did not have linkage data, which left 56019 infants for analysis. There were no cases of kernicterus and no significant differences in rates of cerebral palsy, deafness, developmental delay, or visual abnormalities between the groups. There were suggestions of associations with attention-deficit disorder in the severe hyperbilirubinemia group and with autism in the combined moderate and severe hyperbilirubinemia group.

CONCLUSIONS. There was no increase in adverse effects reported previously to be associated with bilirubin toxicity. Associations with developmental delay, attention-deficit disorder, and autism were observed.

Key Words: hyperbilirubinemia • outcomes • population-based

Abbreviations: TSB—total serum bilirubin • RR—relative risk • CI—confidence interval

Accepted Sep 19, 2007.